Acalabrutinib Plus Venetoclax/Rituximab Yields 100% ORR in Treatment-Naive Mantle Cell Lymphoma
Acalabrutinib plus venetoclax and rituximab generated a 100% response rate in treatment-naive mantle cell lymphoma.
Related Articles
Individualized Bosutinib Dose Adjustments Lend a Manageable AE Profile in Pretreated CML
Jorge Cortes, MD, discusses findings with bosutinib in CML and the importance of dose adjustment as a strategy for managing bosutinib-related AEs.
ONCT-534 Reduces PSA Levels, Is Tolerable in Relapsed/Refractory mCRPC
ONCT-534 reduced prostate-specific antigen levels in patients with relapsed/refractory metastatic castration-resistant prostate cancer.
FDA Grants Priority Review to TLX101-CDx for Glioma Imaging
The FDA has accepted and granted priority review to the new drug application for the glioma imaging agent TLX101-CDx.
COMMANDS Trial Demonstrates Benefit Across Mutations in RS-Positive LR-MDS
During a Case-Based Roundtable® event, Yazan Madanat, MD, discussed a the patient population and outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndrome in…
Pembrolizumab Earns EU Approval in 2 New Indications for Endometrial and Cervical Cancer
Pembrolizumab-based combinations have been approved in Europe in 2 new indications for endometrial and cervical cancer.
Antibody–drug conjugates come of age in oncology – Nature Reviews Drug Discovery
Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the potency of cytotoxic agents. The technology to develop these agents has improved in past…
2024 Regulatory Approvals Across NSCLC Propel the Therapeutic Landscape Forward
Noman Ashraf, MD, discusses the evolving treatment landscape in non–small cell lung cancer following numerous regulatory approvals in the space.
Advances in Targeted Therapies for SCLC Care
Ariel Lopez-Chavez, MD, provides an overview of the most promising advancements in targeted therapies for the treatment of small cell lung cancer.
Adjuvant Ribociclib Revamps HR+/HER2– Breast Cancer Management
Jairam Krishnamurthy, MD, FACP, discusses factors that influence his choice between ribociclib and abemaciclib in the adjuvant breast cancer setting.